Hinge Health (HNGE) Stock Price, News & Analysis

Company Overview

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs. Participants gain access to on-demand exercise regimens, progress tracking via connected sensors and remote clinician support—all designed to address conditions ranging from back and joint pain to post-surgical rehabilitation. The platform also leverages data analytics and outcomes measurement to continually refine its care pathways and demonstrate value to its clients.

Hinge Health has built a leadership team rooted in digital health, physical therapy and behavioral science, led by co-founder and CEO Daniel Perez. Through collaborations with major corporations, insurers and provider networks, the company is expanding its reach across the United States and into select international markets. By simplifying access to high-quality MSK care, Hinge Health seeks to transform how organizations manage one of the most prevalent and costly health challenges globally.

Key Stats

• Today's Range: $49.29 to $50.91
• 50-Day Range: $48.27 to $60.03
• 52-Week Range: $33.42 to $62.18
• Volume: 764,212 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $3.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.47
• Consensus Rating: Moderate Buy

HNGE Stock Analysis - Frequently Asked Questions

How have HNGE shares performed this year?

Hinge Health's stock was trading at $40.15 on January 1st, 2025. Since then, HNGE shares have increased by 23.7% and is now trading at $49.6670.

How were Hinge Health's earnings last quarter?

Hinge Health Inc. (NYSE:HNGE) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($13.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.98) by $8.12. The firm's revenue for the quarter was up 54.9% on a year-over-year basis.

When did Hinge Health IPO?

Hinge Health (HNGE) raised $437 million in an IPO on Thursday, May 22nd 2025. The company issued 13,666,000 shares at $32.00 per share.

When does the company's lock-up period expire?

Hinge Health's lock-up period expires on Tuesday, November 18th. Hinge Health had issued 13,666,000 shares in its IPO on May 22nd. The total size of the offering was $437,312,000 based on an initial share price of $32.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Hinge Health's major shareholders?

Hinge Health's top institutional shareholders include Harbour Capital Advisors LLC (0.01%).

How do I buy shares of Hinge Health?

Shares of HNGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/10/2025
• Next Earnings (Confirmed): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Business Services
• Current Symbol: NYSE:HNGE
• Previous Symbol: NYSE:HNGE
• CIK: 1673743
• Web: N/A
• Phone: (415) 689-8429
• Fax: N/A
• Employees: 1,514
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Hinge Health: $57.47
• High Price Target: $67.00
• Low Price Target: $41.00
• Potential Upside/Downside: +14.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.84
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $480.79 million
• Price / Sales: 8.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 78,435,000
• Free Float: N/A
• Market Cap: $3.94 billion
• Optionable: N/A
• Beta: N/A